High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival

  • Authors:
    • Estrid V.S. Høgdall
    • Julia S. Johansen
    • Susanne K. Kjaer
    • Paul A. Price
    • Lise Christensen
    • Jan Blaakaer
    • Johannes E. Bock
    • Eva Glud
    • Claus K. Høgdall
  • View Affiliations

  • Published online on: September 1, 2003     https://doi.org/10.3892/or.10.5.1535
  • Pages: 1535-1538
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

YKL-40 (human cartilage glycoprotein-39) is a member of family 18 glycosyl hydrolases. YKL-40 is a growth factor and is secreted by cancer cells. High serum levels of YKL-40 in patients with colorectal cancer and recurrent metastatic breast cancer have been associated with a poor prognosis. We evaluated the prognostic value of plasma YKL-40 in patients with primary ovarian cancer (OC). YKL-40 was determined by ELISA in plasma obtained preoperatively from 47 women with stage III OC and in plasma from 79 healthy females. The results showed that plasma YKL-40 was elevated compared to healthy females in 57% of the OC patients and was highest in the patients who died during the follow-up compared to the patients still alive (186 vs. 78 µg/l, p=0.002). Patients with high plasma YKL-40 (>130 µg/l) had significantly (p=0.0003) shorter survival than patients with normal plasma YKL-40. Multivariate Cox regression analysis showed that plasma YKL-40 (RH=3.95; 95% CI, 1.52-10.27; p=0.005) and radicality after primary surgery (RH=4.03; 95% CI, 1.81-8.97; p=0.001) were independent prognostic factors of survival, whereas age, histological type of tumour and serum CA125 had no independent prognostic value. In conclusion, plasma levels of YKL-40 proved of prognostic value in stage III OC patients.

Related Articles

Journal Cover

September-October 2003
Volume 10 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Høgdall EV, Johansen JS, Kjaer SK, Price PA, Christensen L, Blaakaer J, Bock JE, Glud E and Høgdall CK: High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep 10: 1535-1538, 2003
APA
Høgdall, E.V., Johansen, J.S., Kjaer, S.K., Price, P.A., Christensen, L., Blaakaer, J. ... Høgdall, C.K. (2003). High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncology Reports, 10, 1535-1538. https://doi.org/10.3892/or.10.5.1535
MLA
Høgdall, E. V., Johansen, J. S., Kjaer, S. K., Price, P. A., Christensen, L., Blaakaer, J., Bock, J. E., Glud, E., Høgdall, C. K."High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival". Oncology Reports 10.5 (2003): 1535-1538.
Chicago
Høgdall, E. V., Johansen, J. S., Kjaer, S. K., Price, P. A., Christensen, L., Blaakaer, J., Bock, J. E., Glud, E., Høgdall, C. K."High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival". Oncology Reports 10, no. 5 (2003): 1535-1538. https://doi.org/10.3892/or.10.5.1535